| Zacks Company Profile for Heron Therapeutics, Inc. (HRTX : NSDQ) |
|
|
| |
| • Company Description |
| Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.
Number of Employees: 122 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.10 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,937,601 shares |
| Shares Outstanding: 183.36 (millions) |
| Market Capitalization: $201.70 (millions) |
| Beta: 1.30 |
| 52 Week High: $2.68 |
| 52 Week Low: $1.04 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-14.06% |
-16.31% |
| 12 Week |
-17.29% |
-20.72% |
| Year To Date |
-28.10% |
-37.16% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
100 REGENCY FOREST DRIVE SUITE 300
-
CARY,NC 27518
USA |
ph: 858-251-4400
fax: 650-365-6490 |
info@herontx.com |
http://www.herontx.com |
|
|
| |
| • General Corporate Information |
Officers
Craig Collard - Chief Executive Officer and Director
Adam Morgan - Chairman
Ira Duarte - Executive Vice President and Chief Financial Offic
Sharmila Dissanaike - Director
Michael Kaseta - Director
|
|
Peer Information
Heron Therapeutics, Inc. (GSAC)
Heron Therapeutics, Inc. (CASI)
Heron Therapeutics, Inc. (ALCD.)
Heron Therapeutics, Inc. (OMNN)
Heron Therapeutics, Inc. (CGPI.)
Heron Therapeutics, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 427746102
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/26/26
|
|
Share - Related Items
Shares Outstanding: 183.36
Most Recent Split Date: 1.00 (0.05:1)
Beta: 1.30
Market Capitalization: $201.70 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.03 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.09 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 02/26/26 |
|
|
|
| |
